Using PD-L1 as a Biomarker of Response
Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses using PD-L1 as a biomarker of response in melanoma.
Clinical Pearls
Michael A. Postow, MD, attending physician, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses using PD-L1 as a biomarker of response in melanoma.
- There remains a need to determine the utility of PD-L1 as a biomarker of response to PD-1-inhibiting agents.
- Patients with high levels of PD-L1 within their tumor are more likely to respond to PD-1-inhibiting agents.
- Patients that do not express PD-L1 can still benefit from PD-1 blockade.
- Regardless of PD-L1 status, patients will be given the option of being treated with PD-1-inhibiting agents until more data are available.
Recent Videos
Related Content
Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
February 13th 2025Article
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.
Read More
